StockData
CytoMed Therapeutics Ltd logo

CytoMed Therapeutics Ltd (GDTC) stock

GDTCNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Mar 31, 2026Score 4/30
$0.83+0.05 (+6.00%)

Close on Nov 18, 2026Market cap $9.82MP/E –Yield –

CytoMed Therapeutics operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

For fiscal 2025 it was -3.70M SGD. The highest annual figure on record is -849.44K SGD in fiscal 2020.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-3.70M SGD–
FY2024Dec 31, 2024-2.71M SGD–
FY2023Dec 31, 2023-3.53M SGD–
FY2022Dec 31, 2022-1.40M SGD–
FY2021Dec 31, 2021-1.71M SGD–
FY2020Dec 31, 2020-849.44K SGD–

More CytoMed Therapeutics figures

See a number that looks wrong?